KSF News, Updates, & Insights
KSF Defeats Motion to Dismiss in Aimmune Therapeutics Securities Litigation
In re Aimmune Therapeutics, Inc. Securities Litigation, Master File No. 4:20-CV-06733-MMC. On April 29, 2022, the Hon. Maxine M. Chesney entered an Order Denying Defendants’ Motion to Dismiss the Amended Complaint, finding that plaintiffs had adequately alleged false and misleading statements in connection with Aimmune Therapeutics, Inc.’s acquisition by its largest shareholder.